Sequential versus concomitant therapy for eradication of Helicobacter Pylori in patients with perforated duodenal ulcer: A randomized trial
Authors:
Open Access
- 1 January 2016
- journal article
- research article
- Published by Medknow in Saudi Journal of Gastroenterology
- Vol. 22 (4) , 309-15
Abstract
Objectives: Comparison of Helicobacter pylori eradication rates, side effects, compliance, cost, and ulcer recurrence of sequential therapy (ST) with that of concomitant therapy (CT) in patients with perforated duodenal ulcer following simple omental patch closure. Methods: Sixty-eight patients with perforated duodenal ulcer treated with simple closure and found to be H. pylori positive on three months follow-up were randomized to receive either ST or CT for H. pylori eradication. Urease test and Giemsa stain were used to assess for H. pylori eradication status. Follow-up endoscopies were done after 3 months, 6 months, and 1 year to evaluate the ulcer recurrence. Results: H. pylori eradication rates were similar in ST and CT groups on intention-to-treat (ITT) analysis (71.43% vs 81.80%,P = 0.40). Similar eradication rates were also found in per-protocol (PP) analysis (86.20% vs 90%,P = 0.71). Ulcer recurrence rate in ST groups and CT groups at 3 months (17.14% vs 6.06%,P = 0.26), 6 months (22.86% vs 9.09%,P = 0.19), and at 1 year (25.71% vs 15.15%,P = 0.37) of follow-up was also similar by ITT analysis. Compliance and side effects to therapies were comparable between the groups. The most common side effects were diarrhoea and metallic taste in ST and CT groups, respectively. A complete course of ST costs Indian Rupees (INR) 570.00, whereas CT costs INR 1080.00. Conclusion: H. pylori eradication rates, side effects, compliance, cost, and ulcer recurrences were similar between the two groups. The ST was more economical compared with CT.Keywords
This publication has 29 references indexed in Scilit:
- Nonbismuth Quadruple “Concomitant” Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori EradicationJournal of Clinical Gastroenterology, 2013
- Standard triple versus levofloxacin based regimen for eradication ofHelicobacter pyloriWorld Journal of Gastrointestinal Pharmacology and Therapeutics, 2013
- Pilot Studies to Identify the Optimum Duration of Concomitant Helicobacter pylori Eradication Therapy in ThailandHelicobacter, 2012
- Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- Nonbismuth Quadruple (Concomitant) Therapy: Empirical and Tailored Efficacy versus Standard Triple Therapy for Clarithromycin‐Susceptible Helicobacter pylori and versus Sequential Therapy for Clarithromycin‐Resistant StrainsHelicobacter, 2012
- Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pyloriClinical and Experimental Gastroenterology, 2012
- 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trialThe Lancet, 2011
- Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut, 2010
- Sequential and Concomitant Therapy With Four Drugs Is Equally Effective for Eradication of H pylori InfectionClinical Gastroenterology and Hepatology, 2010
- Prevalence of Helicobacter pylori in southern Indian controls and patients with gastroduodenal diseaseJournal of Gastroenterology and Hepatology, 1994